Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawmakers Want HIPAA Data Access Rules Amended To Encourage Consumer ‘Shopping’ For Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Lawmakers at a House hearing discussed amending the HIPAA privacy regulations to allow patients more access to their own data, and to encourage patient participation in selecting their own genetic tests, mammograms or other diagnostics.

You may also be interested in...



Hologic’s Tomosynthesis Improves Cancer Detection Rates Of Mammography In Study

3D breast tomosynthesis improves the recall rate and cancer-detection rate of mammography, according to a retrospective study of 454,850 examinations. The results may be good news for Hologic, which has struggled to accelerate adoption for the technology due to lack of reimbursement.

AIM Act Touted As One Solution To Device Reimbursement Woes

The Accelerating Innovation in Medicine Act, introduced last year with some bipartisan support, was touted at the latest House 21st Century Cures hearing as a self-pay path for seniors to get access to newly-approved devices not yet covered under Medicare, and to give manufacturers time to collect needed data to support reimbursement.

News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay

Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel